A Phase III, Randomized, Placebo‐Controlled Study of the Efficacy and Safety of 10% Liquid Intravenous Immunoglobulin (IGIV) for the Treatment of Multifocal Motor Neuropathy (MMN). Issue 9 (17th September 2013)